Skye Bioscience to Present at H.C. Wainwright Global Life Sciences Conference
March 03, 2021 08:37 ET
|
Skye Bioscience, Inc.
San Diego, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic...
Skye Bioscience to Participate in Investment Conferences in February
February 03, 2021 09:09 ET
|
Skye Bioscience, Inc.
San Diego, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic...
Emerald Bioscience Launches Rebrand Including Name Change to Skye Bioscience
January 19, 2021 08:30 ET
|
Skye Bioscience, Inc.
San Diego, Calif, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic...
Emerald Bioscience to Change Name and Trading Symbol Effective Tuesday, January 19th
January 15, 2021 13:30 ET
|
Emerald Bioscience, Inc.
San Diego, Calif, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“EMBI” or the “Company”), a biopharmaceutical company focused on developing proprietary,...
Emerald Bioscience to Present at the KCSA Cannabis Investor Conference
January 05, 2021 08:30 ET
|
Emerald Bioscience, Inc.
San Diego, Calif, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a biopharmaceutical company focused on developing differentiated, proprietary...
Emerald Bioscience Reports that Superior Reduction of Intraocular Pressure of its Unique Nanoemulsion Formulation of THCVHS is Published in Peer-Reviewed Journal
December 16, 2020 08:30 ET
|
Emerald Bioscience, Inc.
Drug Delivery and Translational Research article highlights significantly better drug load and duration of activity of prodrug of THC compared to leading commercial drugs for treating glaucoma San...
Emerald Bioscience to Present at the Benzinga Global Small Cap Virtual Conference
December 07, 2020 08:45 ET
|
Emerald Bioscience, Inc.
San Diego, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a preclinical-stage biopharmaceutical company focused on developing...
Emerald Bioscience Provides Corporate Update
September 30, 2020 08:30 ET
|
Emerald Bioscience, Inc.
Renewed team and capital focused on advancing lead compound for glaucoma into human studies Ongoing development of lead compound, THCVHS, includes near-term preclinical assessments of neuroprotection...
Emerald Bioscience to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 03, 2020 11:39 ET
|
Emerald Bioscience, Inc.
San Diego, CA, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI a preclinical-stage biopharmaceutical company focused on the development of proprietary first-in-class...
Emerald Bioscience Appoints Biotech Veteran Dr. Margaret Dalesandro to Board of Directors
August 13, 2020 08:30 ET
|
Emerald Bioscience, Inc.
San Diego, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a preclinical-stage biopharmaceutical company focused on the development of...